Rizzo JD, Lichtin AE, Woolf SH, et al: Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107, 2002
Gabrilove JL: Cancer therapy: New strategies and treatment modalities for optimizing patient outcomes. Semin Hematol 38:1-7, 2001 (suppl 7)
Bottomley A, Thomas R, Van Steen K, et al: Human recombinant erythropoietin and quality of life: A wonder drug or something to wonder about? Lancet Oncol 3:145-153, 2002
Littlewood TJ, Bajetta E, Nortier JW, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebocontrolled trial. J Clin Oncol 19:2865-2874, 2001
Bottomley A, Flechtner H: Quality of life in oncology clinical trials: Present and future challenges. Expert Rev Pharmacoeconomics Outcomes Res 2:67-76, 2002
Steineck G, Helgesen F, Adolfsson J, et al: Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347:790-796, 2002
Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormoneresistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996
